2 results
Approved WMOCompleted
To evaluate the safety and tolerability of escalating doses of oral sunitinib in combination with standard doses of intravenous ifosfamide in patients with solid malignancies.
Approved WMOCompleted
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…